Is TRIL A Good Stock To Buy According To Hedge Funds?
Is TRIL A Good Stock To Buy According To Hedge Funds?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to Trillium Therapeutics Inc. (NASDAQ:TRIL) changed recently.
包括沃伦·巴菲特(Warren Buffett)、大卫·泰珀(David Tepper)和斯坦·德鲁肯米勒(Stan Druckenmiler)在内的许多知名投资者一直对当前的牛市持谨慎态度，并在最近几周股市再创新高时错失了良机。另一方面，科技对冲基金毫不畏惧，实现了两位数的超越大盘的收益。金融、能源和工业类股表现不佳，但自3月份以来带来强劲回报的许多股票仍然非常强劲，对冲基金实际上增加了这些股票的头寸。在这篇文章中，我们将了解对冲基金情绪是如何延龄草治疗公司(Trillium Treateutics Inc.)(纳斯达克股票代码：TRIL)最近发生了变化。
Is TRIL a good stock to buy?Trillium Therapeutics Inc. (NASDAQ:TRIL) shareholders have witnessed an increase in activity from the world's largest hedge funds lately. Trillium Therapeutics Inc. (NASDAQ:TRIL) was in 32 hedge funds' portfolios at the end of September. The all time high for this statistic is 25. This means the bullish number of hedge fund positions in this stock currently sits at its all time high. Our calculations also showed that TRIL isn't among the 30 most popular stocks among hedge funds (click for Q3 rankings and see the video for a quick look at the top 5 stocks).Video: Watch our video about the top 5 most popular hedge fund stocks.
Tril是值得买的好股票吗？延龄治疗公司(纳斯达克交易代码：TRIL)的股东最近见证了世界上最大的对冲基金的活动增加。截至9月底，Trillium治疗公司(纳斯达克市场代码：TRIL)在32家对冲基金的投资组合中。这一统计数据的历史最高值是25。这意味着这只股票的看涨对冲基金头寸数量目前处于历史最高水平。我们的计算还显示，Tril不在对冲基金最受欢迎的30只股票之列(点击查看第三季度排名，快速浏览前5只股票的视频)。视频：观看我们关于最受欢迎的5只对冲基金股票的视频。
In today’s marketplace there are a large number of tools investors put to use to evaluate their stock investments. A duo of the best tools are hedge fund and insider trading activity. Our experts have shown that, historically, those who follow the best picks of the best hedge fund managers can trounce the market by a healthy margin (see the details here).Richard Driehaus of Driehaus Capital
在今天的欧元™市场上，投资者可以使用大量的工具来评估他们的股票投资。对冲基金和内幕交易活动是两个最好的工具。我们的专家已经证明，从历史上看，那些遵循最好的对冲基金经理的人可以以健康的优势击败市场(请看这里的详细信息)。Driehaus Capital的理查德·德里豪斯(Richard Driehaus)
At Insider Monkey we leave no stone unturned when looking for the next great investment idea. For example, the House passed a landmark bill decriminalizing marijuana. So, we are checking out this under the radarcannabis stockright now. We go through lists like the 15best blue chip stocks to buyto pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our website. Now we're going to analyze the recent hedge fund action surrounding Trillium Therapeutics Inc. (NASDAQ:TRIL).Do Hedge Funds Think TRIL Is A Good Stock To Buy Now?
在Insider Monkey，我们不遗余力地寻找下一个伟大的投资点子。例如，众议院通过了一项里程碑式的法案，将大麻合法化。所以，我们正在秘密调查这件事大麻库存现在就来。我们看了一遍像15个人这样的清单最值得买入的蓝筹股挑选最好的大盘股进行买入。尽管我们只推荐了我们分析的公司中很小一部分的头寸，但我们会尽可能多地查看股票。我们读对冲基金投资者的信，听对冲基金会议上的股票推介。您可以在我们的网站上订阅我们的免费每日时事通讯。现在我们来分析一下最近对冲基金围绕Trillium治疗公司(纳斯达克股票代码：TRIL)采取的行动。对冲基金认为Tril是现在值得买入的股票吗？
At Q3's end, a total of 32 of the hedge funds tracked by Insider Monkey were long this stock, a change of 28% from the previous quarter. On the other hand, there were a total of 4 hedge funds with a bullish position in TRIL a year ago. So, let's examine which hedge funds were among the top holders of the stock and which hedge funds were making big moves.
截至第三季度末，在Insider Monkey追踪的对冲基金中，共有32只基金做多这只股票，较上一季度变化了28%。另一方面，一年前TRIL共有4家对冲基金持有看涨头寸。那么，让我们来看看哪些对冲基金是这只股票的最大持有者之一，哪些对冲基金正在采取重大行动。
More specifically, RA Capital Management was the largest shareholder of Trillium Therapeutics Inc. (NASDAQ:TRIL), with a stake worth $87.6 million reported as of the end of September. Trailing RA Capital Management was Avoro Capital Advisors (venBio Select Advisor), which amassed a stake valued at $78.2 million. Citadel Investment Group, Frazier Healthcare Partners, and Cormorant Asset Management were also very fond of the stock, becoming one of the largest hedge fund holders of the company. In terms of the portfolio weights assigned to each position Ghost Tree Capital allocated the biggest weight to Trillium Therapeutics Inc. (NASDAQ:TRIL), around 8.01% of its 13F portfolio. Frazier Healthcare Partners is also relatively very bullish on the stock, designating 3.55 percent of its 13F equity portfolio to TRIL.
更具体地说，RA资本管理公司是Trillium治疗公司(纳斯达克市场代码：TRIL)的最大股东，截至9月底的报告价值8760万美元。紧随其后的是Avoro Capital Advisors(VenBio Select Advisor)，它积累了价值7820万美元的股份。Citadel Investment Group、Frazier Healthcare Partners和Cormorant Asset Management也非常喜欢这只股票，成为一该公司最大的对冲基金持有者。就分配给每个职位的投资组合权重而言，Ghost Tree Capital分配给Trillium治疗公司(纳斯达克市场代码：TRIL)的权重最大，约占其13F投资组合的8.01%。Frazier Healthcare Partners也相对非常看好该股，将其13F股票投资组合中的3.55%指定为Tril。
As one would reasonably expect, key money managers were breaking ground themselves. Cormorant Asset Management, managed by Bihua Chen, initiated the biggest position in Trillium Therapeutics Inc. (NASDAQ:TRIL). Cormorant Asset Management had $35.5 million invested in the company at the end of the quarter. Richard Driehaus's Driehaus Capital also initiated a $12.8 million position during the quarter. The following funds were also among the new TRIL investors: Manfred Yu's Acuta Capital Partners, Benjamin A. Smith's Laurion Capital Management, and Matthew L Pinz's Pinz Capital.
正如人们可以合理预期的那样，关键的基金经理们自己也在破土动工。由陈碧华(Bihua Chen)管理的Cormorant资产管理公司(Cormorant Asset Management)在延龄治疗公司(纳斯达克市场代码：TRIL)设立了最大的头寸。截至季度末，Cormorant Asset Management向该公司投资了3550万美元。理查德·德里豪斯(Richard Driehaus)的德里豪斯资本(Driehaus Capital)也在本季度启动了1280万美元的头寸。以下基金也在新的TRIL投资者之列：曼弗雷德·余(Manfred Yu)的Acuta Capital Partners、本杰明·A·史密斯(Benjamin A.Smith)的Laurion Capital Management和马修·L·品茨(Matthew L Pinz)的Pinz Capital。
Let's now review hedge fund activity in other stocks - not necessarily in the same industry as Trillium Therapeutics Inc. (NASDAQ:TRIL) but similarly valued. These stocks are First Merchants Corporation (NASDAQ:FRME), Alexander's, Inc. (NYSE:ALX), Seabridge Gold, Inc. (NYSE:SA), CBIZ, Inc. (NYSE:CBZ), ACM Research, Inc. (NASDAQ:ACMR), Columbia Property Trust Inc (NYSE:CXP), and Xperi Holding Corporation (NASDAQ:XPER). This group of stocks' market caps match TRIL's market cap.
现在让我们回顾一下对冲基金在其他股票中的活动--不一定与Trillium Treateutics Inc.(纳斯达克股票代码：TRIL)在同一行业，但估值相似。这些股票是第一招商局(纳斯达克市场代码：FRME)，亚历山大百货公司。(纽约证券交易所代码：ALX)，Seabbridge Gold，Inc.。(纽约证券交易所代码：SA)，CBIZ，Inc.。(纽约证券交易所代码：CBZ)，ACM研究公司(纳斯达克股票代码：ACMR)，哥伦比亚房地产信托公司(纽约证券交易所股票代码：CXP)，以及Xperi控股公司(纳斯达克股票代码：XPER)这组股票的市值与Tril的市值相当。
[table] Ticker, No of HFs with positions, Total Value of HF Positions (x1000), Change in HF Position FRME,15,65819,4 ALX,10,99516,2 SA,10,68702,2 CBZ,14,182425,0 ACMR,16,129786,5 CXP,15,47691,-1 XPER,23,96085,1 Average,14.7,98575,1.9 [/table]
[表格]股票代码，带位置的HFs数量，HF位置的总值(X1000)，HF位置变化FRME，15,65819，4 ALX，10,99516，2 SA，10,68702，2 CBZ，14,182425，0 ACMR，16,129786，5 CxP，15,47691，-1 Xper，23,96085，1平均值，14.7,98575，1.9[/TABLE]
View table here if you experience formatting issues.
如果您遇到格式问题，请在此处查看表格。
As you can see these stocks had an average of 14.7 hedge funds with bullish positions and the average amount invested in these stocks was $99 million. That figure was $465 million in TRIL's case. Xperi Holding Corporation (NASDAQ:XPER) is the most popular stock in this table. On the other hand Alexander's, Inc. (NYSE:ALX) is the least popular one with only 10 bullish hedge fund positions. Compared to these stocks Trillium Therapeutics Inc. (NASDAQ:TRIL) is more popular among hedge funds. Our overall hedge fund sentiment score for TRIL is 90. Stocks with higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score. Our calculations showed that top 20 most popular stocks among hedge funds returned 41.3% in 2019 and outperformed the S&P 500 ETF (SPY) by 10 percentage points. These stocks gained 33.3% in 2020 through December 18th and still beat the market by 16.4 percentage points. Unfortunately TRIL wasn't nearly as popular as these 20 stocks and hedge funds that were betting on TRIL were disappointed as the stock returned -12% since the end of the third quarter (through 12/18) and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks among hedge funds as most of these stocks already outperformed the market in 2020.
正如你所看到的，这些股票平均有14.7只持有看涨头寸的对冲基金，平均投资于这些股票的金额为9900万美元。在特里尔的案例中，这个数字是4.65亿美元。Xperi Holding Corporation(纳斯达克股票代码：XPER)是本表中最受欢迎的股票。另一方面，亚历山大公司(NYSE：ALX)是最不受欢迎的公司，只有10个看涨对冲基金头寸。与这些股票相比，Trillium治疗公司(纳斯达克股票代码：TRIL)在对冲基金中更受欢迎。我们对TRIL的整体对冲基金情绪评分为90分。与其他股票相比，对冲基金持仓数量较多的股票，以及相对于其历史区间的股票，获得更高的情绪得分。我们的计算显示，对冲基金中最受欢迎的前20只股票在2019年的回报率为41.3%，表现比标准普尔500指数交易所交易基金(SPY)高出10个百分点。截至12月18日，这些股票在2020年上涨了33.3%，但仍比大盘高出16.4个百分点。不幸的是，TRIL远不如这20只股票受欢迎，押注TRIL的对冲基金感到失望，因为该股自第三季度末(截至12月12日)的回报率为-12%，表现逊于大盘。如果你有兴趣投资具有巨大上涨潜力的大盘股，你应该看看对冲基金中最受欢迎的20只股票，因为这些股票中的大多数在2020年已经跑赢了大盘。
Get real-time email alerts: Follow Trillium Therapeutics Inc. (NASDAQ:TRIL)
获取实时电子邮件提醒：关注Trillium Treateutics Inc.(纳斯达克股票代码：TRIL)
Disclosure: None. This article was originally published at Insider Monkey.
披露：没有。本文最初发表在“内幕猴子”(Insider Monkey)杂志上。
Related ContentHow to Best Use Insider Monkey To Increase Your ReturnsTop 20 Richest People In The World12 Highest Paying Part Time Jobs for College Students
相关内容如何最好地利用内幕猴子来提高回报率世界上最富有的20人12名大学生收入最高的兼职工作
译文内容由第三方软件翻译。